NVCT director files Form 3 listing 35,150 direct-share stake
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
Nuvectis Pharma (NVCT) reported an initial Form 3 for a director with an event date of 09/22/2025. The filing lists beneficial ownership of 35,150 shares of common stock (direct), plus 295 shares (indirect) and 120 shares (indirect) held as custodian for a son. Table II shows no derivative securities. The form was signed by Juan Sanchez on 10/31/2025.
Positive
- None.
Negative
- None.
Insider Trade Summary
3 transactions reported
Mixed
3 txns
Insider
Sanchez Juan
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 35,150 shares (Direct);
Common Stock — 295 shares (Indirect, As custodian for son)
Footnotes (1)
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Nuvectis Pharma (NVCT) file?
A Form 3, the initial statement of beneficial ownership under Section 16.
Who is the reporting person on NVCT’s Form 3?
Juan Sanchez, who signed the form on 10/31/2025.
What is the reporting person’s relationship to NVCT?
The individual is a Director.
What indirect holdings are reported on the Form 3?
Indirect holdings include 295 shares and 120 shares, each held as custodian for a son.
Were any derivative securities reported?
No. Table II shows no derivative securities listed.
What is the event date on the Form 3?
The event date is 09/22/2025.